Compounds > deferitrin
Page last updated: 2024-10-15

deferitrin

Description

4'-hydroxydesazadesferrithiocin: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135413558
CHEMBL ID432481
SCHEMBL ID1272026
MeSH IDM0494705

Synonyms (37)

Synonym
gt-56252
deferitrin ,
(s)-4'-(ho)-dadft
CHEMBL432481
gt-56-252
gt56-252
deferitrin (usan/inn)
D08899
239101-33-8
(+)-(4s)-2-(2,4-dihydroxyphenyl)-4-methyl-4,5-dihydrothiazole-4-carboxylic acid
4,5-dihydro-2-(2,4-dihydroxyphenyl)-4-methylthiazol-4-(s)-carboxylic acid
unii-t69y9ldn44
t69y9ldn44 ,
4'-hydroxydesazadesferrithiocin
deferitrin [usan:inn]
4-thiazolecarboxylic acid, 2-(2,4-dihydroxyphenyl)-4,5-dihydro-4-methyl-, (4s)-
deferitrin [usan]
deferitrin [inn]
4,5-dihydro-2-(2,4-dihydroxyphenyl)-4-methylthiazole-4(s)-carboxylic acid
4,5-dihydro-2-(2,4-dihydroxyphenyl)-4-methylthiazole-4-(s)-carboxylic acid
OEUUFNIKLCFNLN-LLVKDONJSA-N
SCHEMBL1272026
(s)-2-(2,4-dihydroxyphenyl)-4-methyl-4,5-dihydrothiazole-4-carboxylic acid
EX-A214
AKOS027326768
iron-chelator
(4s)-2-(2,4-dihydroxyphenyl)-4,5-dihydro-4-methyl-4-thiazolecarboxylic acid
(4s)-2-(2,4-dihydroxyphenyl)-4-methyl-5h-1,3-thiazole-4-carboxylic acid
Q27289730
HY-108260
CS-0027833
gt 56 252
deferitringt-56-252
gt 56252
(s)-2-(2,4-dihydroxyphenyl)-4-methyl-4,5-dihydrothiazole-4-carboxylicacid
AC-36805
PD118368
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (86)

Assay IDTitleYearJournalArticle
AID407343Biodistribution in Sprague-Dawley rat kidney assessed per gram tissue wet weight at 300 umol/kg, po after 1 hr2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID407317Iron-clearing efficiency in non-iron-overloaded Sprague-Dawley rat at 300 umol/kg, po after 24 hrs relative to control2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID1243023Octanol-TRIS buffer lipophilicity, logD (apparent partition coefficient) of the compound at pH 7.4 by shake flask method2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Metabolically programmed iron chelators.
AID407324Iron-clearing efficiency in iron-overloaded Cebus apella at 150 umol/kg, po after 2 days relative to control2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID264448Iron-clearing efficiency in non-iron-overloaded Sprague-Dawley rat at 300 umol/kg, po2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
(S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: a solution to nephrotoxicity.
AID407344Biodistribution in Sprague-Dawley rat kidney assessed per gram tissue wet weight at 300 umol/kg, sc after 2 hrs2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID126488Iron clearing activity when administered 150 uM/kg orally to Cebus apella Primates (n = 4) [% stool/% urine = 86/14]2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Methoxylation of desazadesferrithiocin analogues: enhanced iron clearing efficiency.
AID251611Iron clearing efficiency in urine of rodents following a subcutaneous dosage of 300 umol/kg2005Journal of medicinal chemistry, Jun-16, Volume: 48, Issue:12
Polyamine-vectored iron chelators: the role of charge.
AID407363Biodistribution in Sprague-Dawley rat plasma at 300 umol/kg, po after 2 hrs2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID1243018Iron clearing efficiency in bile duct cannulated Sprague-Dawley rat assessed as clearance of iron in urine at 300 umol/kg, po measured at 3 hrs intervals for up to 48 hrs relative to control2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Metabolically programmed iron chelators.
AID407323Iron-clearing efficiency in non-iron-overloaded Sprague-Dawley rat at 300 umol/kg, sc after 24 hrs relative to control2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID407365Biodistribution in Sprague-Dawley rat plasma at 300 umol/kg, po after 4 hrs2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID264453Distribution in Sprague-Dawley rat plasma at 300 umol/kg, sc2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
(S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: a solution to nephrotoxicity.
AID273541Iron clearing efficiency in Sprague-Dawley rat at 300 umol/kg, po2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
The design, synthesis, and evaluation of organ-specific iron chelators.
AID248014Inhibitory concentration against growth of murine L1210 cells at 96 hours2005Journal of medicinal chemistry, Jun-16, Volume: 48, Issue:12
Polyamine-vectored iron chelators: the role of charge.
AID1243017Iron clearing efficiency in bile duct cannulated Sprague-Dawley rat assessed as clearance of iron in feces at 300 umol/kg, po measured at 3 hrs intervals for up to 48 hrs relative to control2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Metabolically programmed iron chelators.
AID251609Iron clearing efficiency in bile of rodents following a subcutaneous dosage of 300 umol/kg2005Journal of medicinal chemistry, Jun-16, Volume: 48, Issue:12
Polyamine-vectored iron chelators: the role of charge.
AID264451Iron-clearing efficiency in iron-loaded Cebus apella at 150 umol/kg, sc2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
(S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: a solution to nephrotoxicity.
AID407345Biodistribution in Sprague-Dawley rat kidney assessed per gram tissue wet weight at 300 umol/kg, po after 2 hrs2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID407352Biodistribution in Sprague-Dawley rat heart assessed per gram tissue wet weight at 300 umol/kg, sc after 4 hrs2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID407341Biodistribution in Sprague-Dawley rat liver assessed per gram tissue wet weight at 300 umol/kg, po after 4 hrs2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID407336Biodistribution in Sprague-Dawley rat liver assessed per gram tissue wet weight at 300 umol/kg, sc after 1 hr2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID407340Biodistribution in Sprague-Dawley rat liver assessed per gram tissue wet weight at 300 umol/kg, sc after 4 hrs2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID407337Biodistribution in Sprague-Dawley rat liver assessed per gram tissue wet weight at 300 umol/kg, po after 1 hr2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID1243051Performance ratio, ratio of iron clearing efficiency in bile duct cannulated Cebus apella at 150 umol/kg, po to iron clearing efficiency in bile duct cannulated Sprague-Dawley rat at 300 umol/kg, po2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Metabolically programmed iron chelators.
AID407356Biodistribution in Sprague-Dawley rat pancreas assessed per gram tissue wet weight at 300 umol/kg, sc after 2 hrs2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID407364Biodistribution in Sprague-Dawley rat plasma at 300 umol/kg, sc after 4 hrs2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID273543Iron clearing efficiency in monkey at 150 umol/kg2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
The design, synthesis, and evaluation of organ-specific iron chelators.
AID273549Drug level in Sprague-Dawley rat kidney at 300 umol/kg, sc after 1 hr2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
The design, synthesis, and evaluation of organ-specific iron chelators.
AID1243016Iron clearing efficiency in bile duct cannulated Sprague-Dawley rat assessed as clearance of iron at 300 umol/kg, po measured at 3 hrs intervals for up to 48 hrs relative to control2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Metabolically programmed iron chelators.
AID407358Biodistribution in Sprague-Dawley rat pancreas assessed per gram tissue wet weight at 300 umol/kg, sc after 4 hrs2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID273547Drug level in Sprague-Dawley rat plasma at 300 umol/kg, sc after 2 hrs2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
The design, synthesis, and evaluation of organ-specific iron chelators.
AID407357Biodistribution in Sprague-Dawley rat pancreas assessed per gram tissue wet weight at 300 umol/kg, po after 2 hrs2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID248013Inhibitory concentration against growth of murine L1210 cells at 48 hours2005Journal of medicinal chemistry, Jun-16, Volume: 48, Issue:12
Polyamine-vectored iron chelators: the role of charge.
AID407318Iron-clearing efficiency in non-iron-overloaded Sprague-Dawley rat at 150 umol/kg, po after 24 hrs relative to control2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID273545Toxicity in Sprague-Dawley rat at 384 umol/kg, po2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
The design, synthesis, and evaluation of organ-specific iron chelators.
AID1243014Iron clearing efficiency in bile duct cannulated Cebus apella assessed as clearance of iron in feces at 150 umol/kg, po measured at 3 hrs intervals for up to 48 hrs relative to control2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Metabolically programmed iron chelators.
AID407325Iron-clearing efficiency in iron-overloaded Cebus apella at 150 umol/kg, sc after 2 days relative to control2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID407338Biodistribution in Sprague-Dawley rat liver assessed per gram tissue wet weight at 300 umol/kg, sc after 2 hrs2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID251613Iron clearing efficiency in bile-duct-cannulated rodents following a subcutaneous dosage of 300 umol/kg2005Journal of medicinal chemistry, Jun-16, Volume: 48, Issue:12
Polyamine-vectored iron chelators: the role of charge.
AID407354Biodistribution in Sprague-Dawley rat pancreas assessed per gram tissue wet weight at 300 umol/kg, sc after 1 hr2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID264449Iron-clearing efficiency in non-iron-overloaded Sprague-Dawley rat at 300 umol/kg, sc2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
(S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: a solution to nephrotoxicity.
AID407348Biodistribution in Sprague-Dawley rat heart assessed per gram tissue wet weight at 300 umol/kg, sc after 1 hr2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID407353Biodistribution in Sprague-Dawley rat heart assessed per gram tissue wet weight at 300 umol/kg, po after 4 hrs2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID244579Ability to compete with [3H]SPD for the polyamine transport apparatus in L1210 cells2005Journal of medicinal chemistry, Jun-16, Volume: 48, Issue:12
Polyamine-vectored iron chelators: the role of charge.
AID264450Iron-clearing efficiency in iron-loaded Cebus apella at 150 umol/kg, po2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
(S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: a solution to nephrotoxicity.
AID126983The compound was tested in vivo for the iron clearing activity against non -iron-overloaded Cebus apella monkey at a concentration of 75 uM/Kg1999Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13
Effects of C-4 stereochemistry and C-4' hydroxylation on the iron clearing efficiency and toxicity of desferrithiocin analogues.
AID407327Toxicity in iron-overloaded Sprague-Dawley rat assessed as survival at 119 umol/kg/day, po after 30 days by non-renal perfusion protocol2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID407339Biodistribution in Sprague-Dawley rat liver assessed per gram tissue wet weight at 300 umol/kg, po after 2 hrs2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID407321Iron-clearing efficiency in non-iron-overloaded Sprague-Dawley rat bile assessed as iron excretion at 150 umol/kg, po2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID264459Distribution in Sprague-Dawley rat pancreas at 300 umol/kg, sc after 8 hrs2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
(S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: a solution to nephrotoxicity.
AID264447Apparent partition coefficient of the compound at pH7.42006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
(S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: a solution to nephrotoxicity.
AID407349Biodistribution in Sprague-Dawley rat heart assessed per gram tissue wet weight at 300 umol/kg, po after 1 hr2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID407360Biodistribution in Sprague-Dawley rat plasma at 300 umol/kg, sc after 1 hr2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID193267The compound was tested in vivo for the iron clearing activity against non-iron-overloaded-bile duct cannulated rat, at a concentration of 150 uM/Kg1999Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13
Effects of C-4 stereochemistry and C-4' hydroxylation on the iron clearing efficiency and toxicity of desferrithiocin analogues.
AID407359Biodistribution in Sprague-Dawley rat pancreas assessed per gram tissue wet weight at 300 umol/kg, po after 4 hrs2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID126979The compound was tested in vivo for the iron clearing activity against non -iron-overloaded Cebus apella monkey at a concentration of 150 uM/Kg.1999Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13
Effects of C-4 stereochemistry and C-4' hydroxylation on the iron clearing efficiency and toxicity of desferrithiocin analogues.
AID1243015Iron clearing efficiency in bile duct cannulated Cebus apella assessed as clearance of iron in urine at 150 umol/kg, po measured at 3 hrs intervals for up to 48 hrs relative to control2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Metabolically programmed iron chelators.
AID264460Distribution in Sprague-Dawley rat pancreas at 300 umol/kg, sc after 4 hrs2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
(S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: a solution to nephrotoxicity.
AID264456Distribution in Sprague-Dawley rat liver at 300 umol/kg, sc after 2 hrs2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
(S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: a solution to nephrotoxicity.
AID407362Biodistribution in Sprague-Dawley rat plasma at 300 umol/kg, sc after 2 hrs2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID264466Distribution in Sprague-Dawley rat kidney at 300 umol/kg, sc after 2 hrs2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
(S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: a solution to nephrotoxicity.
AID264461Distribution in Sprague-Dawley rat pancreas at 300 umol/kg, sc after 6 hrs2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
(S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: a solution to nephrotoxicity.
AID407351Biodistribution in Sprague-Dawley rat heart assessed per gram tissue wet weight at 300 umol/kg, po after 2 hrs2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID250592Percentage of iron clearing efficiency was measured in monkey after administration at 150 umol/kg (n=4)2005Journal of medicinal chemistry, Feb-10, Volume: 48, Issue:3
Partition-variant desferrithiocin analogues: organ targeting and increased iron clearance.
AID1243013Iron clearing efficiency in bile duct cannulated Cebus apella assessed as clearance of iron at 150 umol/kg, po measured at 3 hrs intervals for up to 48 hrs relative to control2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Metabolically programmed iron chelators.
AID407342Biodistribution in Sprague-Dawley rat kidney assessed per gram tissue wet weight at 300 umol/kg, sc after 1 hr2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID407346Biodistribution in Sprague-Dawley rat kidney assessed per gram tissue wet weight at 300 umol/kg, sc after 4 hrs2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID273542Partition coefficient, log P of the compound2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
The design, synthesis, and evaluation of organ-specific iron chelators.
AID407361Biodistribution in Sprague-Dawley rat plasma at 300 umol/kg, po after 1 hr2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID19215Partition coefficient (logP)2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Methoxylation of desazadesferrithiocin analogues: enhanced iron clearing efficiency.
AID407350Biodistribution in Sprague-Dawley rat heart assessed per gram tissue wet weight at 300 umol/kg, sc after 2 hrs2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID237616Lipophilicity (Log Papp) was measured at pH 7.4; Activity expressed as the log of the fraction in the octanol layer2005Journal of medicinal chemistry, Feb-10, Volume: 48, Issue:3
Partition-variant desferrithiocin analogues: organ targeting and increased iron clearance.
AID264458Distribution in Sprague-Dawley rat pancreas at 300 umol/kg, sc after 2 hrs2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
(S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: a solution to nephrotoxicity.
AID264457Distribution in Sprague-Dawley rat liver at 300 umol/kg, sc after 8 hrs2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
(S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: a solution to nephrotoxicity.
AID407355Biodistribution in Sprague-Dawley rat pancreas assessed per gram tissue wet weight at 300 umol/kg, po after 1 hr2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID407335Nephrotoxicity in Sprague-Dawley rat assessed as heavy vacuolized renal tubules at 273 umol/kg, po bid for 7 days by renal perfusion studies2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID252381Intracellular concentration was determined in murine L1210 cells after treatment with 100 uM compound for 48 h2005Journal of medicinal chemistry, Jun-16, Volume: 48, Issue:12
Polyamine-vectored iron chelators: the role of charge.
AID273550Drug level in Sprague-Dawley rat liver at 300 umol/kg, sc after 0.5 hrs2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
The design, synthesis, and evaluation of organ-specific iron chelators.
AID264467Distribution in Sprague-Dawley rat kidney at 300 umol/kg, sc after 8 hrs2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
(S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: a solution to nephrotoxicity.
AID407347Biodistribution in Sprague-Dawley rat kidney assessed per gram tissue wet weight at 300 umol/kg, po after 4 hrs2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID273548Drug level in Sprague-Dawley rat kidney at 300 umol/kg, sc after 0.5 hrs2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
The design, synthesis, and evaluation of organ-specific iron chelators.
AID273546Drug level in Sprague-Dawley rat plasma at 300 umol/kg, sc after 0.5 hrs2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
The design, synthesis, and evaluation of organ-specific iron chelators.
AID264462Distribution in Sprague-Dawley rat heart at 300 umol/kg, sc after 2 hrs2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
(S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: a solution to nephrotoxicity.
AID407320Iron-clearing efficiency in non-iron-overloaded Sprague-Dawley rat bile assessed as iron excretion at 300 umol/kg, po2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.
AID249436Ratio of intracellular concentration to that of treatment concentration in L1210 cells2005Journal of medicinal chemistry, Jun-16, Volume: 48, Issue:12
Polyamine-vectored iron chelators: the role of charge.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (7.14)18.2507
2000's12 (85.71)29.6817
2010's1 (7.14)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (28.57%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (71.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
deferiprone
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.. deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.		4.55404-pyridonesiron chelator;
protective agent
deferoxamine
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.. desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.		4.5640acyclic desferrioxaminebacterial metabolite;
ferroptosis inhibitor;
iron chelator;
siderophore
n(1), n(12)-diethylspermine
N(1), N(12)-diethylspermine: structure in first source. N(1),N(12)-diethylspermine : A substituted spermine that is spermine in which a hydrogen attached to each of the primary amino groups has been replaced by an ethyl group.		2.0210polyazaalkane;
secondary amino compound;
substituted spermine;
tetramine		antineoplastic agent
thiazoles
[no description available]		5.72801,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
triazoles
Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.		4.04201,2,3-triazole
deferasirox
Deferasirox: A triazole and benzoate derivative that acts as a selective iron chelator. It is used in the management of chronic IRON OVERLOAD due to blood transfusion or non-transfusion dependent THALASSEMIA.. deferasirox : A member of the class of triazoles, deferasirox is 1,2,4-triazole substituted by a 4-carboxyphenyl group at position 1 and by 2-hydroxyphenyl groups at positions 3 and 5. An orally active iron chelator, it is used to manage chronic iron overload in patients receiving long-term blood transfusions.		4.0420benzoic acids;
monocarboxylic acid;
phenols;
triazoles		iron chelator
ConditionIndicatedRelationship StrengthStudiesTrials
Iron Overload
An excessive accumulation of iron in the body due to a greater than normal absorption of iron from the gastrointestinal tract or from parenteral injection. This may arise from idiopathic hemochromatosis, excessive iron intake, chronic alcoholism, certain types of refractory anemia, or transfusional hemosiderosis. (From Churchill's Illustrated Medical Dictionary, 1989)		05.3670
Bronze Diabetes
[description not available]		03.8220
Thalassemias
[description not available]		03.8220
Hemochromatosis
A disorder of iron metabolism characterized by a triad of HEMOSIDEROSIS; LIVER CIRRHOSIS; and DIABETES MELLITUS. It is caused by massive iron deposits in parenchymal cells that may develop after a prolonged increase of iron absorption. (Jablonski's Dictionary of Syndromes & Eponymic Diseases, 2d ed)		03.8220
Thalassemia
A group of hereditary hemolytic anemias in which there is decreased synthesis of one or more hemoglobin polypeptide chains. There are several genetic types with clinical pictures ranging from barely detectable hematologic abnormality to severe and fatal anemia.		03.8220
Anemia, Cooley's
[description not available]		03.3520
beta-Thalassemia
A disorder characterized by reduced synthesis of the beta chains of hemoglobin. There is retardation of hemoglobin A synthesis in the heterozygous form (thalassemia minor), which is asymptomatic, while in the homozygous form (thalassemia major, Cooley's anemia, Mediterranean anemia, erythroblastic anemia), which can result in severe complications and even death, hemoglobin A synthesis is absent.		15.3520
Acute Hemolytic Transfusion Reaction
[description not available]		03.3520
Transfusion Reaction
Complications of BLOOD TRANSFUSION. Included adverse reactions are common allergic and febrile reactions; hemolytic (delayed and acute) reactions; and other non-hemolytic adverse reactions such as infections and adverse immune reactions related to immunocompatibility.		03.3520